{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:48:41Z","timestamp":1794019721627,"version":"4.8.0"},"reference-count":35,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"unspecified","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CTUQQR-Dec22\/100006"],"award-info":[{"award-number":["CTUQQR-Dec22\/100006"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre"},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["220589\/Z\/20\/Z"],"award-info":[{"award-number":["220589\/Z\/20\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001922","name":"Efficacy and Mechanism Evaluation Programme","doi-asserted-by":"publisher","award":["NIHR154840"],"award-info":[{"award-number":["NIHR154840"]}],"id":[{"id":"10.13039\/501100001922","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,12]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment through targeted disruption of the physiological pathways that maintain tissue tolerance, but which are co-opted by cancers to evade immunosurveillance. Thus, the resultant T-cell activity often causes immune-related adverse events including immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA). ICI-IA results in functional impairment that frequently persists, even after ICI discontinuation, with substantial quality-of-life impacts for cancer survivors.<\/jats:p>\n                    <jats:p>A high-quality body of evidence to guide ICI-IA management remains an unmet need. Pharmacological treatment may be prolonged, typically begins with non-specific immunosuppression, including systemic steroids, and is usually only rationalised to more targeted therapy in resistant cases. Moreover, retrospective data suggest the high dose glucocorticoids sometimes used in new-onset ICI-IA may be associated with worse cancer outcomes.<\/jats:p>\n                    <jats:p>Tumour necrosis factor (TNF) inhibition strategies are well established with excellent efficacy and safety profiles in \u2018spontaneous\u2019 inflammatory arthritides including rheumatoid and psoriatic arthritis. Mechanistic evidence from ex vivo and murine studies also supports the utility of anti-TNF therapy for steroid-refractory cases of ICI-IA. Although good clinical responses have been reported in this setting, the REACT trial (REmission induction of Arthritis caused by Cancer ImmunoTherapy) aims to provide randomised and robust clinical evidence for deploying targeted therapy earlier in ICI-IA management. It will test whether up-front anti-TNF therapy can more effectively and quickly control symptoms, reduce glucocorticoid exposure, prevent early ICI discontinuation and increase the frequency of drug-free ICI-IA remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>REACT is a prospective, multicentre, open-label, superiority, two-arm, randomised controlled clinical trial to guide initial therapy for patients with ICI-IA. The trial will compare the current standard of care (initial prednisolone; Arm A) with the anti-TNF drug, adalimumab without glucocorticoids (Arm B).<\/jats:p>\n                    <jats:p>The primary outcome is glucocorticoid-free arthritis remission rate at 24\u2009weeks where remission is defined as: (i) No use of systemic or intra-articular glucocorticoids (except when used for adrenal insufficiency) within 4\u2009weeks prior to assessment at 24\u2009weeks; and (ii) absence of synovitis on clinical examination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol was approved by East Midlands\u2014Leicester South Research Ethics Committee on 31-Oct-2024 (Ref: 24\/EM\/0202). Participants are required to provide written informed consent. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN18217497\">ISRCTN18217497<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-116847","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:20:27Z","timestamp":1772547627000},"page":"e116847","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"isrctn18217497","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-549X","authenticated-orcid":false,"given":"Benjamin A","family":"Fisher","sequence":"first","affiliation":[{"name":"School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK"},{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rowe","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Hodson","sequence":"additional","affiliation":[{"name":"Patient partner, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manpreet","family":"Wilkhu","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Williams","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Turner","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Allard","sequence":"additional","affiliation":[{"name":"Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Blake","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bombardieri","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P","family":"Cope","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish","family":"Dubey","sequence":"additional","affiliation":[{"name":"Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"},{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kulveer","family":"Mankia","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"},{"name":"NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamir","family":"Malley","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Royal Free Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Derriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Payne","sequence":"additional","affiliation":[{"name":"Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[{"name":"Sir Bobby Robson Cancer Trials Research Centre, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"},{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tilby","sequence":"additional","affiliation":[{"name":"Oncology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Tillett","sequence":"additional","affiliation":[{"name":"Oncology Department, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Wong","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Queen Alexandra Hospital, Portsmouth University Hospital NHS Trust, Portsmouth, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wu","sequence":"additional","affiliation":[{"name":"Centre for Inflammation Biology and Cancer Immunology, King\u2019s College London, London, UK"},{"name":"Department of Medical Oncology, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Filer","sequence":"additional","affiliation":[{"name":"School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Pratt","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Musculoskeletal Unit, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK"},{"name":"NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Pallan","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Homer","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"},{"name":"NIHR Birmingham Biomedical Research Centre, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"2026062609353142000_16.3.e116847.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2026062609353142000_16.3.e116847.2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.41587","article-title":"Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications","volume":"73","author":"Cappelli","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026062609353142000_16.3.e116847.3","doi-asserted-by":"crossref","first-page":"vii29","DOI":"10.1093\/rheumatology\/kez536","article-title":"Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective","volume":"58","author":"Steven","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026062609353142000_16.3.e116847.4","unstructured":"Market Data Forecast . Europe checkpoint inhibitors market research report \u2013 segmented by type, application & country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - industry analysis on size, share, trends & growth forecast (2025 to 2033). 2025. Available: https:\/\/www.marketdataforecast.com\/market-reports\/europe-checkpoint-inhibitors-market [Accessed 19 Aug 2025]."},{"key":"2026062609353142000_16.3.e116847.5","doi-asserted-by":"crossref","unstructured":"Wang R , Singaraju A , Marks KE , et al . Clonally expanded CD38. bioRxiv 2021;2021. doi:10.1101\/2021.10.19.464961","DOI":"10.1101\/2021.10.19.464961"},{"key":"2026062609353142000_16.3.e116847.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216109"},{"key":"2026062609353142000_16.3.e116847.7","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-020-00133-8","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps","volume":"4","author":"Cappelli","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2026062609353142000_16.3.e116847.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026062609353142000_16.3.e116847.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026062609353142000_16.3.e116847.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2025.100496","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis","volume":"25","author":"Fisher","year":"2025","journal-title":"Clin Med (Lond)"},{"key":"2026062609353142000_16.3.e116847.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1283"},{"key":"2026062609353142000_16.3.e116847.12","unstructured":"Croft A , Pallan L , Steven N , et al . Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis. Arthritis Rheumatol 2021;73."},{"key":"2026062609353142000_16.3.e116847.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.142729"},{"key":"2026062609353142000_16.3.e116847.14","doi-asserted-by":"crossref","first-page":"101479","DOI":"10.1016\/j.berh.2019.101479","article-title":"When the first visit to the rheumatologist is established rheumatoid arthritis","volume":"33","author":"Taylor","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026062609353142000_16.3.e116847.15","unstructured":"Bass A-W , Reid P , Sparks J , et al . Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis. Arthritis Rheumatol 2022;74."},{"key":"2026062609353142000_16.3.e116847.16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/BOR.0000000000000701","article-title":"Treatment of immune checkpoint inhibitor-induced inflammatory arthritis","volume":"32","author":"Jeurling","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"2026062609353142000_16.3.e116847.17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000281","article-title":"Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy","volume":"8","author":"Murray-Brown","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062609353142000_16.3.e116847.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"2026062609353142000_16.3.e116847.19","doi-asserted-by":"publisher","DOI":"10.1038\/10552"},{"key":"2026062609353142000_16.3.e116847.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-2524"},{"key":"2026062609353142000_16.3.e116847.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"2026062609353142000_16.3.e116847.22","doi-asserted-by":"crossref","first-page":"955812","DOI":"10.3389\/fimmu.2022.955812","article-title":"TNF-\u03b1 inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"key":"2026062609353142000_16.3.e116847.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3449"},{"key":"2026062609353142000_16.3.e116847.24","doi-asserted-by":"crossref","first-page":"S936","DOI":"10.1016\/j.annonc.2022.07.972","article-title":"846P Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial","volume":"33","author":"Meyer","year":"2022","journal-title":"Ann Oncol"},{"key":"2026062609353142000_16.3.e116847.25","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s10067-020-05420-w","article-title":"Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?","volume":"40","author":"Chatzidionysiou","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026062609353142000_16.3.e116847.26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026062609353142000_16.3.e116847.27","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfab144"},{"key":"2026062609353142000_16.3.e116847.28","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/rheumatology\/key234","article-title":"High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis","volume":"57","author":"Ford","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026062609353142000_16.3.e116847.29","unstructured":"National Cancer Institute (NCI) . Common terminology criteria for adverse events (CTCAE), version 5.0. 2017. Available: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events [Accessed 12 Aug 2025]."},{"key":"2026062609353142000_16.3.e116847.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223885"},{"key":"2026062609353142000_16.3.e116847.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.004"},{"key":"2026062609353142000_16.3.e116847.32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"2026062609353142000_16.3.e116847.33","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.221127"},{"key":"2026062609353142000_16.3.e116847.34","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12509"},{"key":"2026062609353142000_16.3.e116847.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3322"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-116847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:36:56Z","timestamp":1782491816000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-116847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,3]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2026-116847"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-116847","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}